ArticleJournal of inflammation research2025
Integrated Multi-Omics Analyses Reveal Innovative Diagnostic and Therapeutic Targets Associated with Atopic Dermatitis.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Screening of Metabolic Reprogramming-Related Diagnostic Biomarkers and Analysis of Immune Heterogeneity in Atopic Dermatitis Based on Multi-Cohort Validation.Clinical, cosmetic and investigational dermatology · 2026Article
- The Neuroimmune Axis in Atopic Dermatitis: From Pathogenic Mechanisms to Targeted Neuroimmunotherapy.Journal of inflammation research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atopic dermatitis (AD) is a chronic skin disorder that impacts patients' physical and mental health. Diagnosing AD mainly depends on evaluating medical history and symptoms, as there are no universally accepted biomarkers for it. Identifying novel, reliable biomarkers is crucial to enhance diagnostic accuracy, reduce healthcare costs, and aid in developing new treatments. Methods: Data from the Gene Expression Omnibus database were used to identify potential AD biomarkers through Weighted Gene Co-expression Network Analysis and machine-learning. External datasets confirmed these biomarkers' diagnostic utility and their effectiveness in assessing clinical treatment. We also gathered peripheral blood mononuclear cells from healthy individuals and AD patients to validate these biomarkers' diagnostic capability for AD. Correlation analyses linked these biomarkers to AD severity indicators. Euclidean distance clustering was employed to assess the ability of these biomarkers to distinguish between healthy individuals and AD patients. The study also examined their relationships with major inflammatory pathways in AD to understand their mechanisms. Results: The study identified Ribonucleotide Reductase Regulatory Subunit M2 (RRM2), Late Cornified Envelope 3D (LCE3D), Cornifelin (CNFN), and Small Proline Rich Protein 2G (SPRR2G) as biomarkers with greater diagnostic value for AD than traditional biomarkers like eosinophil count and IgE levels. Treatment led to decreased expression of RRM2, LCE3D, and CNFN in AD patients' skin, indicating their potential as markers for evaluating treatment efficacy. LCE3D, CNFN, and SPRR2G correlated with AD severity indicators such as the SCORAD score and serum IgE levels. Additionally, the overexpression of these biomarkers was linked to the activation of inflammatory pathways, suggesting their role in AD pathogenesis and progression. Conclusion: Our study identifies RRM2, LCE3D, CNFN, and SPRR2G as novel biomarkers for diagnosing AD in peripheral blood and lesional tissues, with potential for assessing disease severity, evaluating treatment efficacy, and serving as targets for diagnosis and treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.